

US-Korea enter into joint investment collaboration for biopharma

21 January 2025 | News

For the expansion of promising South Korean biotech companies into the US market



GordonMD Global Investments LP, a US-based investment manager focused exclusively on global public and private biopharmaceutical investments, and Partners Investment Co., a South Korean-based investment firm with more than 20 years experience investing in healthcare and life sciences, have agreed to enter into a joint investment collaboration.

This venture leverages the combined knowledge and resources of two firms with decades of investing experience in both public and private growth companies, extensive relationships with industry participants and management teams plus practical medical training.

“Collaborating with Partners positions us to pursue and invest in breakthrough therapies not only in the US but also in South Korea, a country increasingly active in the biopharmaceutical space,” said Craig Gordon, MD, Founder and Chief Executive Officer of GordonMD. “We are eager to identify and help nurture innovation and growth among pre-clinical and clinical biopharmaceutical companies,” he added.

“This venture could be a groundbreaking initiative for the expansion of promising South Korean biotech companies into the US market. We believe this partnership will serve as a bridge connecting biotech companies in both countries and foster global innovation,” stated Jae An, PhD, Managing Director of Partners.